Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Medical Oncology

Your Treatment Plan: Options and Standards of Care

At a Glance

Exocrine pancreatic cancer treatment is tailored to whether the tumor can be removed, whether it has spread, the cancer subtype, and your overall health. Options may include surgery, chemotherapy, radiation, targeted treatment, clinical trials, and supportive care.

Standard treatment for exocrine pancreatic cancer is no longer “one size fits all.” Your medical team will customize your plan based on several factors: your overall fitness (performance status), the physical location of the tumor (its resectability), distant metastasis, and the specific biology of the cancer cells (whether it is PDAC or PACC) [1][2].

Treatment Pathways by Category

Your treatment path relies on multidisciplinary planning.

  • Resectable (Surgery First): For tumors that do not touch major blood vessels and have not spread, the standard approach is often surgery followed by adjuvant chemotherapy [1]. The goal of chemotherapy after surgery is to kill any microscopic cancer cells that might remain [3]. However, even for resectable disease, some centers may consider giving chemotherapy before surgery depending on institutional protocols and tumor features.
  • Borderline Resectable (Chemo First): Because these tumors are touching nearby vessels, the standard of care is neoadjuvant therapy—chemotherapy given before surgery [4][5]. This aims to shrink the tumor away from the vessels to ensure the surgeon can achieve “clean margins” [6].
  • Locally Advanced (Systemic First): These tumors heavily involve major arteries and cannot be removed initially. Treatment begins with intensive chemotherapy. If the cancer remains stable and does not spread, your team may add radiation therapy (such as SBRT) to help control the tumor locally [7][8]. In rare cases, this can shrink the tumor enough to make surgery an option later [9].
  • Metastatic (Systemic Focus): When cancer has spread to other organs, the focus is on “systemic” treatment that travels through the entire bloodstream [1]. The goal is to control the cancer, extend life, and maintain quality of life.

Common Chemotherapy Regimens

Chemotherapy regimen choice depends heavily on your age, organ function, existing neuropathies, and overall strength.

  1. FOLFIRINOX (or modified FOLFIRINOX): A powerful combination of four drugs. It is often the preferred choice for fit patients because of its high efficacy, though it can have more side effects like fatigue and diarrhea [3][10].
  2. Gemcitabine + Nab-paclitaxel: An alternative combination used across multiple stages. While sometimes considered if FOLFIRINOX isn’t suitable, it carries its own risks of nerve damage and bone marrow suppression [1][11].
  3. NALIRIFOX: A newer three-drug combination (including nanoliposomal irinotecan) explicitly approved as a first-line option for metastatic PDAC [12].

For frailer patients, a single drug (like gemcitabine alone), modified dosages, or clinical trials may be the most appropriate choice.

Special Considerations for PACC

If you have the rarer Pancreatic Acinar Cell Carcinoma (PACC), your treatment may look different. Because PACC is rare, evidence is largely based on retrospective data rather than large randomized trials. However, these studies suggest PACC cells may respond favorably to platinum-based drugs (like oxaliplatin in FOLFIRINOX) and fluoropyrimidine drugs (like 5-FU) compared to standard gemcitabine [2][13]. Because PACC is more likely to have mutations in DNA-repair genes, your team will watch your molecular profiling closely to see if targeted therapies are an option [14][15].

The Essential Role of Supportive Care

Current guidelines emphasize that palliative care (supportive care) should begin at the same time as your cancer treatment, not as a replacement for it [16]. Early integration of supportive care has been shown to improve quality of life and may even help you stay on your chemotherapy for longer by managing side effects effectively [17][18].

This team focuses on:

  • Pain Management: Using medications or nerve blocks (like a celiac plexus block) to target the nerves near the pancreas [19][20].
  • Nutrition: Ensuring you are taking the correct dose of pancreatic enzymes to prevent weight loss [21].
  • Symptom Relief: Managing nausea, fatigue, and the emotional stress of the diagnosis [22].

Common questions in this guide

How is an exocrine pancreatic cancer treatment plan chosen?
Your team considers whether the tumor can be removed safely, whether it has spread, whether it is PDAC or PACC, your overall health and organ function, and your treatment goals. These factors help determine the order of surgery, chemotherapy, radiation, and supportive care.
What treatment is used when pancreatic cancer can be removed?
For a resectable tumor that has not spread and does not involve major blood vessels, surgery is often followed by chemotherapy to destroy cancer cells that may remain. Some centers may give chemotherapy before surgery based on tumor features and local practice.
What chemotherapy options are used for exocrine pancreatic cancer?
Common options include FOLFIRINOX, gemcitabine with nab-paclitaxel, and NALIRIFOX for certain metastatic PDAC cases. The choice depends on fitness, age, organ function, nerve problems, disease stage, and expected side effects; people who are frail may receive a single drug, adjusted doses, or a clinical trial.
Can locally advanced pancreatic cancer become eligible for surgery?
Locally advanced tumors usually begin with chemotherapy because they involve major arteries. If the cancer stays stable and does not spread, radiation such as SBRT may help control it, and in rare cases enough shrinkage may make surgery possible.
Is treatment different for pancreatic acinar cell carcinoma?
PACC is rare, so treatment evidence is less certain than it is for more common pancreatic ductal cancer. Doctors may consider platinum-based and fluoropyrimidine drugs, and molecular testing can look for DNA-repair changes that may open targeted treatment options.
Why is palliative care offered during pancreatic cancer treatment?
Palliative care is supportive care that can start alongside chemotherapy or other cancer treatment; it is not a replacement for treatment. The team can help manage pain, nausea, fatigue, emotional stress, nutrition, and digestive problems, including pancreatic enzyme needs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my 'resectability' category, what is the exact sequence of my treatment plan (e.g., surgery first or chemo first)?
  2. 2.Which chemotherapy regimen is recommended for me—FOLFIRINOX, Gem/Nab-paclitaxel, or NALIRIFOX—and why was it chosen over the others?
  3. 3.If my tumor is borderline or locally advanced, what criteria will we use to decide if I am ready for surgery after my initial chemotherapy?
  4. 4.For my PACC diagnosis, why are we choosing a platinum-based regimen instead of standard gemcitabine?
  5. 5.Is there a role for 'precision' radiation like SBRT in my case to help with local control or pain?
  6. 6.When can I meet with the palliative care team to help manage my symptoms and side effects during chemotherapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Pancreatic Cancer: A Review.

    Park W, Chawla A, O'Reilly EM

    JAMA 2021; (326(9)):851-862 doi:10.1001/jama.2021.13027.

    PMID: 34547082
  2. 2

    [Pancreatic acinar cell carcinoma: Clinical and theranostic characteristics].

    Marques A, Mas L, Dardenne A, et al.

    Bulletin du cancer 2026; (113(6)):806-815 doi:10.1016/j.bulcan.2026.01.007.

    PMID: 41820118
  3. 3

    FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

    Conroy T, Hammel P, Hebbar M, et al.

    The New England journal of medicine 2018; (379(25)):2395-2406 doi:10.1056/NEJMoa1809775.

    PMID: 30575490
  4. 4

    Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis.

    Dickerson LD, Gittens J, Brunning C, et al.

    BJS open 2025; (9(2)) doi:10.1093/bjsopen/zrae172.

    PMID: 40126570
  5. 5

    Defining and Treating Borderline Resectable Pancreatic Cancer.

    Perri G, Prakash L, Katz MHG

    Current treatment options in oncology 2020; (21(9)):71 doi:10.1007/s11864-020-00769-1.

    PMID: 32725270
  6. 6

    Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.

    Versteijne E, Suker M, Groothuis K, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(16)):1763-1773 doi:10.1200/JCO.19.02274.

    PMID: 32105518
  7. 7

    Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.

    Kunzmann V, Siveke JT, Algül H, et al.

    The lancet. Gastroenterology & hepatology 2021; (6(2)):128-138 doi:10.1016/S2468-1253(20)30330-7.

    PMID: 33338442
  8. 8

    Stereotactic body radiotherapy for pancreatic cancer - A systematic review of prospective data.

    Shouman MA, Fuchs F, Walter F, et al.

    Clinical and translational radiation oncology 2024; (45()):100738 doi:10.1016/j.ctro.2024.100738.

    PMID: 38370495
  9. 9

    Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.

    Murphy JE, Wo JY, Ryan DP, et al.

    JAMA oncology 2019; (5(7)):1020-1027 doi:10.1001/jamaoncol.2019.0892.

    PMID: 31145418
  10. 10

    Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).

    Arima S, Kawahira M, Shimokawa M, et al.

    Pancreas 2021; (50(7)):957-964 doi:10.1097/MPA.0000000000001859.

    PMID: 34347735
  11. 11

    Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

    Sohal DP, Mangu PB, Khorana AA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(23)):2784-96 doi:10.1200/JCO.2016.67.1412.

    PMID: 27247222
  12. 12

    Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study.

    Thambamroong T, Meesart R, Prasongsook N, et al.

    BMJ oncology 2026; (5(2)):e001085 doi:10.1136/bmjonc-2026-001085.

    PMID: 42422059
  13. 13

    Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature.

    Xu JY, Guan WL, Lu SX, et al.

    Clinical Medicine Insights. Oncology 2022; (16()):11795549221090186 doi:10.1177/11795549221090186.

    PMID: 35509769
  14. 14

    Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC.

    Florou V, Elliott A, Bailey MH, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(17)):3408-3417 doi:10.1158/1078-0432.CCR-22-3724.

    PMID: 37266563
  15. 15

    Whole genome and transcriptome analysis of pancreatic acinar cell carcinoma elucidates mechanisms of homologous recombination deficiency and unravels novel relevant fusion events.

    Delgado-de la Mora J, Al Assaad M, Karaaslan S, et al.

    Pathology, research and practice 2025; (266()):155798 doi:10.1016/j.prp.2024.155798.

    PMID: 39731868
  16. 16

    Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

    Khorana AA, Mangu PB, Berlin J, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(21)):2541-56 doi:10.1200/JCO.2016.67.5553.

    PMID: 27247221
  17. 17

    Early Palliative Care Is Associated With Reduced Emergency Department Utilization in Pancreatic Cancer.

    Bevins J, Bhulani N, Goksu SY, et al.

    American journal of clinical oncology 2021; (44(5)):181-186 doi:10.1097/COC.0000000000000802.

    PMID: 33710133
  18. 18

    Palliative Care and End-of-Life Care in Metastatic Pancreatic Cancer.

    O'Brien J, Halsey B, Connors M, et al.

    Journal of palliative medicine 2025; (28(2)):217-223 doi:10.1089/jpm.2024.0313.

    PMID: 39636708
  19. 19

    Surgical Palliation for Advanced Pancreas Cancer.

    Jacobs CS, Vitello DJ, Chawla A

    The Surgical clinics of North America 2024; (104(5)):1121-1135 doi:10.1016/j.suc.2024.04.008.

    PMID: 39237168
  20. 20

    What are the current and potential future roles for endoscopic ultrasound in the treatment of pancreatic cancer?

    Oh SY, Irani S, Kozarek RA

    World journal of gastrointestinal endoscopy 2016; (8(7)):319-29 doi:10.4253/wjge.v8.i7.319.

    PMID: 27076870
  21. 21

    Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer.

    Pezzilli R, Caccialanza R, Capurso G, et al.

    Cancers 2020; (12(2)) doi:10.3390/cancers12020275.

    PMID: 31979186
  22. 22

    The impact of early palliative care on the quality of life of patients with advanced pancreatic cancer: The IMPERATIVE case-crossover study.

    Kim CA, Lelond S, Daeninck PJ, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2023; (31(4)):250 doi:10.1007/s00520-023-07709-3.

    PMID: 37022483

This page is for informational purposes only and does not constitute medical advice. Your oncology team should use your tumor type, stage, resectability, health, and goals to create your personalized treatment plan.

Get notified when new evidence is published on exocrine pancreatic carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.